Trial Profile
Chewed Versus Integral Pill of Ticagrelor in All Patients Undergoing Percutaneous Coronary intervention--a Platelet Reactivity and Patient Outcomes Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jan 2023
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary)
- Indications Coronary artery disease
- Focus Pharmacodynamics
- Sponsors Aurora Advanced Healthcare
- 21 Dec 2022 Status changed from active, no longer recruiting to completed.
- 16 Nov 2020 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2020.
- 16 Nov 2020 Planned End Date changed from 31 Jul 2020 to 31 Jul 2021.